Izun Pharmaceuticals Reports Positive Data for Oral PerioPatch® in the Treatment of Periodontitis

PerioPatch®, a novel oral trans-mucosal patch system that reduces inflammation and promotes tissue repair, has been shown to significantly reduce pocket depth (PD) and to generate an increase in attachment level (AL) in patients with advanced periodontal disease

NEW YORK--()--Izun Pharmaceuticals Corporation (“Izun” www.izunpharma.com), an emerging specialty pharmaceutical company which focuses on developing best in class pharmaceutical products derived from botanical sources today reported the results of a clinical study conducted at the University of North Carolina Chapel Hill (“UNC”). The 80 patient study compared scaling and root planing (SRP) in conjunction with PerioPatch treatment versus SRP alone. The study demonstrated that PerioPatch treatment significantly reduced pocket depth (PD) and increased attachment level (AL) gain relative to control group in treated patients with advanced periodontal disease.

David W. Paquette, DMD, MPH, DMSc, of Stony Brook University School of Dental Medicine, who designed and oversaw the clinical trial remarked, “This clinical study demonstrates that adjunctive PerioPatch treatment reduces the signs of inflammatory periodontal disease beyond conventional therapy. This outcome is a major improvement in the management of periodontal disease in patients. Additionally, PerioPatch represents the first topical anti-inflammatory product that may be applied by both professionals and patients.”

These findings clinically confirm animal data and other clinical trials that the use of PerioPatch will assist in repairing the damage to the gums that develops from periodontal disease. Both primary (reduction of PD) and secondary (AL gain) endpoints of the study were met and were statistically significant. These significant improvements were evident at one month and continued to improve at two and three months, which represented the completion of the evaluation period. The current data extend previously published clinical reports which demonstrated that the PerioPatch can improve the above parameters as well as decrease bleeding upon probing and gingival inflammation at 2, 4 and 6 weeks.

Pre-clinical studies in animal trials demonstrated that treatment with PerioPatch results in more rapid healing as a result of increased collagen production and accelerated tissue revascularization. Such data correlate well with the gingival repair that was noted both in the UNC study and in previously conducted clinical trials.

Dr. William Levine, CEO and Chairman of Izun Pharmaceuticals Corp. stated, “Results of the UNC study support the conclusion that PerioPatch is a breakthrough treatment for periodontal disease and is the most effective topical oral product for reducing gingival inflammation and promoting healing. PerioPatch should thus be integrated into the routine treatment protocol for periodontal disease, a market with estimated annual sales of $2 billion in 2017.”

PerioPatch has regulatory approval in the United States and Canada, as well as in the European Union.

About Izun Pharmaceuticals

Izun Pharmaceuticals is a US-based pharmaceutical company with a wholly owned R&D center in Israel. Izun’s technology platform allows it to develop botanical drugs by optimizing and purifying the extracted botanical compounds to yield polymolecular drug candidates. These patented products are designed to impact on multiple specific receptor targets. The main therapeutic focus is on agents that can reduce inflammation and accelerate healing. Izun is currently active in developing topical therapeutic products for a number of indications including oral care, oncology support, wound care, women’s health care, gastrointestinal disease and dermatologic conditions. Izun uses the inherent advantage of the natural botanical sources to deliver robust clinical results with an excellent safety profile. Izun has received regulatory approval for a number of oral care products that are currently being marketed. A number of clinical studies are in progress for additional indications, including diabetic foot ulcers, oral mucositis and atrophic vaginitis.

Izun Disclosure Notice: This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “to,” “plan,” “expect,” “believe,” “anticipate,” “intend,” “could,” “should,” “would,” “estimate,” or “continue,” or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Investors are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company’s ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company’s control.

Investors are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.

Contacts

Izun Pharmaceuticals Corporation
Dr. William Z. Levine, 1-212-618-6357
CEO and Chairman
Fax: 1-212-618-6309
E mail:wzlevine@izunpharma.com
Website: www.izunpharma.com

Contacts

Izun Pharmaceuticals Corporation
Dr. William Z. Levine, 1-212-618-6357
CEO and Chairman
Fax: 1-212-618-6309
E mail:wzlevine@izunpharma.com
Website: www.izunpharma.com